Myeloid differentiation 2 as a therapeutic target of inflammatory disorders

Pharmacology and Therapeutics

Volumn 133, Issue 3, 2012, Pages 291-298

  Park, Sun Hong ^a   Kim, Nam Doo ^b,c   Jung, Jae Kyung ^a   Lee, Chong Kil ^a   Han, Sang Bae ^a   Kim, Youngsoo ^a,c  

^a Chungbuk National University   (South Korea)

^b Equispharm Co   (South Korea)

^c Daegu Gyeongbuk Medical Innovation Foundation   (South Korea)

Author keywords

Gram negative endotoxin; Inflammatory disease; Lipopolysaccharide antagonist; Myeloid differentiation 2; Toll like receptor 4

Indexed keywords

2',4 DIHYDROXY 6' ISOPENTYLOXYCHALCONE; ANTIINFLAMMATORY AGENT; AURANOFIN; B1,1' BIS(ANILINO) 4,4' BIS(NAPHTHALENE) 8,8' DISUFONATE; BACTERIUM LIPOPOLYSACCHARIDE; BINDING PROTEIN; CURCUMIN; DALCETRAPIB; ERITORAN; ESCHERICHIA COLI ENDOTOXIN; INTERLEUKIN 6; INTERLEUKIN 8; ISOXANTHOHUMOL; LIPID A DERIVATIVE; LIPID IVA; MYELOID DIFFERENTIATION 2; N PYRENE MALEIMIDE; PACLITAXEL; PLACEBO; PROTEIN INHIBITOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; XANTHOHUMOL;

ANTIBACTERIAL ACTIVITY; ANTIGEN RECOGNITION; ANTIINFLAMMATORY ACTIVITY; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENDOTOXEMIA; GRAM NEGATIVE BACTERIUM; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; KIDNEY INJURY; KIDNEY ISCHEMIA; LIGAND BINDING; MEDIATOR RELEASE; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SUBARACHNOID HEMORRHAGE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISACCHARIDES; GLYCOLIPIDS; HUMANS; INFLAMMATION; LIPID A; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; SUGAR PHOSPHATES; TOLL-LIKE RECEPTOR 4;

EID: 84856498328     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2011.11.001     Document Type: Review

References (69)

1. D.M. Agnese, J.E. Calvano, S.J. Hahm, S.M. Coyle, S.A. Corbett, and S.E. Calvano Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections J Infect Dis 186 10 2002 1522 1525 (Pubitemid 35286126)
2. S. Akashi, Y. Nagai, H. Ogata, M. Oikawa, K. Fukase, and S. Kusumoto Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition Int Immunol 13 12 2001 1595 1599 (Pubitemid 33133886)
3. S. Akashi, S. Saitoh, Y. Wakabayashi, T. Kikuchi, N. Takamura, and Y. Nagai Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14 J Exp Med 198 7 2003 1035 1042 (Pubitemid 37248619)
4. J. Andra, T. Gutsmann, M. Muller, and A.B. Schromm Interactions between lipid A and serum proteins Adv Exp Med Biol 667 2010 39 51
5. A. Barochia, S. Solomon, X. Cui, C. Natanson, and P.Q. Eichacker Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies Expert Opin Drug Metab Toxicol 7 4 2011 479 494
6. D.M. Brass, J.D. Savov, S.H. Gavett, N. Haykal-Coates, and D.A. Schwartz Subchronic endotoxin inhalation causes persistent airway disease Am J Physiol Lung Cell Mol Physiol 285 3 2003 L755 761
7. N.J. Child, I.A. Yang, M.C. Pulletz, K. de Courcy-Golder, A.L. Andrews, and V.J. Pappachan Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome Biochem Soc Trans 31 Pt 3 2003 652 653 (Pubitemid 36750749)
8. P.N. Cunningham, Y. Wang, R. Guo, G. He, and R.J. Quigg Role of Toll-like receptor 4 in endotoxin-induced acute renal failure J Immunol 172 4 2004 2629 2635 (Pubitemid 38182415)
9. M.L. Demarco, and R.J. Woods From agonist to antagonist: structure and dynamics of innate immune glycoprotein MD-2 upon recognition of variably acylated bacterial endotoxins Mol Immunol 49 1-2 2011 124 133
10. S. Ehrentraut, S. Frede, H. Stapel, T. Mengden, C. Grohe, and J. Fandrey Antagonism of lipopolysaccharide-induced blood pressure attenuation and vascular contractility Arterioscler Thromb Vasc Biol 27 10 2007 2170 2176 (Pubitemid 350287246)
11. H. Ehrentraut, C. Weber, S. Ehrentraut, M. Schwederski, O. Boehm, and P. Knuefermann The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy Eur J Heart Fail 13 6 2011 602 610
12. J. Fang, J. Lu, and A. Holmgren Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity J Biol Chem 280 26 2005 25284 25290 (Pubitemid 40934623)
13. D.T. Golenbock, R.Y. Hampton, N. Qureshi, K. Takayama, and C.R. Raetz Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes J Biol Chem 266 29 1991 19490 19498 (Pubitemid 21908258)
14. H. Gradisar, M.M. Keber, P. Pristovsek, and R. Jerala MD-2 as the target of curcumin in the inhibition of response to LPS J Leukoc Biol 82 4 2007 968 974 (Pubitemid 47511057)
15. M. Green, A. Apel, and F. Stapleton Risk factors and causative organisms in microbial keratitis Cornea 27 1 2008 22 27
16. S. Hadina, J.P. Weiss, P.B. McCray Jr., K. Kulhankova, and P.S. Thorne MD-2-dependent pulmonary immune responses to inhaled lipooligosaccharides: effect of acylation state Am J Respir Cell Mol Biol 38 6 2008 647 654 (Pubitemid 351841565)
17. H. Hatcher, R. Planalp, J. Cho, F.M. Torti, and S.V. Torti Curcumin: from ancient medicine to current clinical trials Cell Mol Life Sci 65 11 2008 1631 1652
18. L.D. Hawkins, W.J. Christ, and D.P. Rossignol Inhibition of endotoxin response by synthetic TLR4 antagonists Curr Top Med Chem 4 11 2004 1147 1171 (Pubitemid 38923439)
19. L. Hou, H. Sasaki, and P. Stashenko Toll-like receptor 4-deficient mice have reduced bone destruction following mixed anaerobic infection Infect Immun 68 8 2000 4681 4687 (Pubitemid 30497741)
20. A. Ianaro, M. Tersigni, and F. D'Acquisto New insight in LPS antagonist Mini Rev Med Chem 9 3 2009 306 317
21. K.I. Jeon, M.S. Byun, and D.M. Jue Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit Exp Mol Med 35 2 2003 61 66
22. R. Jerala Structural biology of the LPS recognition Int J Med Microbiol 297 5 2007 353 363 (Pubitemid 47188054)
23. N. Jurrmann, R. Brigelius-Flohe, and G.F. Bol Curcumin blocks interleukin-1 (IL-1) signaling by inhibiting the recruitment of the IL-1 receptor-associated kinase IRAK in murine thymoma EL-4 cells J Nutr 135 8 2005 1859 1864 (Pubitemid 41099742)
24. K. Kawasaki, S. Akashi, R. Shimazu, T. Yoshida, K. Miyake, and M. Nishijima Mouse toll-like receptor 4-MD-2 complex mediates lipopolysaccharide- mimetic signal transduction by Taxol J Biol Chem 275 4 2000 2251 2254 (Pubitemid 30081977)
25. E.F. Kenny, and L.A. O'Neill Signaling adaptors used by Toll-like receptors: an update Cytokine 43 3 2008 342 349
26. S. Khatri, J.H. Lass, F.P. Heinzel, W.M. Petroll, J. Gomez, and E. Diaconu Regulation of endotoxin-induced keratitis by PECAM-1, MIP-2, and toll-like receptor 4 Invest Ophthalmol Vis Sci 43 7 2002 2278 2284 (Pubitemid 34700659)
27. J.I. Kim, C.J. Lee, M.S. Jin, C.H. Lee, S.G. Paik, and H. Lee Crystal structure of CD14 and its implications for lipopolysaccharide signaling J Biol Chem 280 12 2005 11347 11351 (Pubitemid 40418442)
28. H.M. Kim, B.S. Park, J.I. Kim, S.E. Kim, J. Lee, and S.C. Oh Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran Cell 130 5 2007 906 917 (Pubitemid 47332573)
29. T. Kitazawa, T. Tsujimoto, H. Kawaratani, and H. Fukui Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats J Gastroenterol Hepatol 25 5 2010 1009 1012
30. F.S. Larsen, and P.N. Bjerring Acute liver failure Curr Opin Crit Care 17 2 2011 160 164
31. Q. Lin, M. Li, D. Fang, J. Fang, and S.B. Su The essential roles of Toll-like receptor signaling pathways in sterile inflammatory diseases Int Immunopharmacol 11 10 2011 1422 1432
32. M. Liu, M. Gu, D. Xu, Q. Lv, W. Zhang, and Y. Wu Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury Transplant Proc 42 5 2010 1539 1544
33. K.L. Lohmann, M.L. Vandenplas, M.H. Barton, C.E. Bryant, and J.N. Moore The equine TLR4/MD-2 complex mediates recognition of lipopolysaccharide from Rhodobacter sphaeroides as an agonist J Endotoxin Res 13 4 2007 235 242 (Pubitemid 47618262)
34. Y.C. Lu, W.C. Yeh, and P.S. Ohashi LPS/TLR4 signal transduction pathway Cytokine 42 2 2008 145 151
35. M. Lynn, D.P. Rossignol, J.L. Wheeler, R.J. Kao, C.A. Perdomo, and R. Noveck Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia J Infect Dis 187 4 2003 631 639 (Pubitemid 36250027)
36. C.X. Ma, W.N. Yin, B.W. Cai, J. Wu, J.Y. Wang, and M. He Toll-like receptor 4/nuclear factor-κB signaling detected in brain after early subarachnoid hemorrhage Chin Med J (Engl) 122 13 2009 1575 1581
37. M. Mancek-Keber, H. Gradisar, M. Inigo Pestana, G. Martinez de Tejada, and R. Jerala Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation J Biol Chem 284 29 2009 19493 19500
38. M. Mancek-Keber, and R. Jerala Structural similarity between the hydrophobic fluorescent probe and lipid A as a ligand of MD-2 FASEB J 20 11 2006 1836 1842 (Pubitemid 44933797)
39. M.G. Marcu, Y.J. Jung, S. Lee, E.J. Chung, M.J. Lee, and J. Trepel Curcumin is an inhibitor of p300 histone acetylatransferase Med Chem 2 2 2006 169 174 (Pubitemid 44083157)
40. V. Mata-Haro, C. Cekic, M. Martin, P.M. Chilton, C.R. Casella, and T.C. Mitchell The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4 Science 316 5831 2007 1628 1632 (Pubitemid 46982038)
41. R. Medzhitov, P. Preston-Hurlburt, and C.A. Janeway Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity Nature 388 6640 1997 394 397 (Pubitemid 27334820)
42. A J Biol Chem 285 36 2010 27935 27943
43. J. Meng, E. Lien, and D.T. Golenbock MD-2-mediated ionic interactions between lipid A and TLR4 are essential for receptor activation J Biol Chem 285 12 2010 8695 8702
44. M. Mullarkey, J.R. Rose, J. Bristol, T. Kawata, A. Kimura, and S. Kobayashi Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist J Pharmacol Exp Ther 304 3 2003 1093 1102 (Pubitemid 36254422)
45. M. Muroi, and K. Tanamoto Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa J Biol Chem 281 9 2006 5484 5491 (Pubitemid 43847643)
46. Y. Nagai, S. Akashi, M. Nagafuku, M. Ogata, Y. Iwakura, and S. Akira Essential role of MD-2 in LPS responsiveness and TLR4 distribution Nat Immunol 3 7 2002 667 672 (Pubitemid 34752476)
47. U. Ohto, K. Fukase, K. Miyake, and Y. Satow Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa Science 316 5831 2007 1632 1634 (Pubitemid 46982039)
48. H. Okamoto, F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, and H. Shinkai A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 6792 2000 203 207 (Pubitemid 30469005)
49. B.S. Park, D.H. Song, H.M. Kim, B.S. Choi, H. Lee, and J.O. Lee The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex Nature 458 7242 2009 1191 1195
50. M.R. Peluso, C.L. Miranda, D.J. Hobbs, R.R. Proteau, and J.F. Stevens Xanthohumol and related prenylated flavonoids inhibit inflammatory cytokine production in LPS-activated THP-1 monocytes: structure-activity relationships and in silico binding to myeloid differentiation protein-2 (MD-2) Planta Med 76 14 2010 1536 1543
51. A. Poltorak, X. He, I. Smirnova, M.Y. Liu, C. Van Huffel, and X. Du Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene Science 282 5396 1998 2085 2088 (Pubitemid 29001265)
52. N. Resman, H. Gradisar, J. Vasl, M.M. Keber, P. Pristovsek, and R. Jerala Taxanes inhibit human TLR4 signaling by binding to MD-2 FEBS Lett 582 28 2008 3929 3934
53. T.W. Rice, A.P. Wheeler, G.R. Bernard, J.L. Vincent, D.C. Angus, and N. Aikawa A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis Crit Care Med 38 8 2010 1685 1694
54. L.A. Ridnour, R.A. Winters, N. Ercal, and D.R. Spitz Measurement of glutathione, glutathione disulfide, and other thiols in mammalian cell and tissue homogenates using high-performance liquid chromatography separation of N-(1-pyrenyl)maleimide derivatives Methods Enzymol 299 1999 258 267 (Pubitemid 28483898)
55. E.T. Rietschel, T. Kirikae, F.U. Schade, U. Mamat, G. Schmidt, and H. Loppnow Bacterial endotoxin: molecular relationships of structure to activity and function FASEB J 8 2 1994 217 225 (Pubitemid 24067145)
56. E. Roh, H.S. Lee, J.A. Kwak, J.T. Hong, S.Y. Nam, and S.H. Jung MD-2 as the target of nonlipid chalcone in the inhibition of endotoxin LPS-induced TLR4 activity J Infect Dis 203 7 2011 1012 1020
57. J.D. Savov, D.M. Brass, B.L. Lawson, E. McElvania-Tekippe, J.K. Walker, and D.A. Schwartz Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide Am J Physiol Lung Cell Mol Physiol 289 2 2005 L329 337
58. A.B. Schromm, K. Brandenburg, H. Loppnow, A.P. Moran, M.H. Koch, and E.T. Rietschel Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion Eur J Biochem 267 7 2000 2008 2013 (Pubitemid 30185287)
59. A. Shimamoto, A.J. Chong, M. Yada, S. Shomura, H. Takayama, and A.J. Fleisig Inhibition of Toll-like receptor4 with eritoran attenuates myocardial ischemia-reperfusion injury Circulation 114 1 Suppl 2006 I270 274
60. Y. Sun, and E. Pearlman Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564) Invest Ophthalmol Vis Sci 50 3 2009 1247 1254
61. K. Takashima, N. Matsunaga, M. Yoshimatsu, K. Hazeki, T. Kaisho, and M. Uekata Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model Br J Pharmacol 157 7 2009 1250 1262
62. K. Tanamoto, and S. Azumi Salmonella-type heptaacylated lipid A is inactive and acts as an antagonist of lipopolysaccharide action on human line cells J Immunol 164 6 2000 3149 3156 (Pubitemid 30148976)
63. M. Tidswell, W. Tillis, S.P. Larosa, M. Lynn, A.E. Wittek, and R. Kao Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis Crit Care Med 38 1 2010 72 83
64. M.L. van Iersel, J.P. Ploemen, M. Lo Bello, G. Federici, and P.J. van Bladeren Interactions of α, β-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1 Chem Biol Interact 108 1-2 1997 67 78 (Pubitemid 28057494)
65. A. Visintin, K.A. Halmen, E. Latz, B.G. Monks, and D.T. Golenbock Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 co-receptor, MD-2 J Immunol 175 10 2005 6465 6472 (Pubitemid 41598888)
66. M. Yamada, T. Ichikawa, T. Yamano, F. Kikumoto, Y. Nishikimi, and N. Tamura Optically active cyclohexene derivative as a new antisepsis agent: an efficient synthesis of ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242) Chem Pharm Bull (Tokyo) 54 1 2006 58 62 (Pubitemid 43036750)
67. M. Yamamoto, and S. Akira Lipid A receptor TLR4-mediated signaling pathways Adv Exp Med Biol 667 2009 59 68
68. S.M. Zimmer, J. Liu, J.L. Clayton, D.S. Stephens, and J.P. Snyder Paclitaxel binding to human and murine MD-2 J Biol Chem 283 41 2008 27916 27926
69. J. Zweigner, R.R. Schumann, and J.R. Weber The role of lipopolysaccharide-binding protein in modulating the innate immune response Microbes Infect 8 3 2006 946 952